Dermfree Wart Corn Remover

Description

No description information is available for the specified drug.

Uses and Indications

This drug is indicated for the removal of warts and corns. It is intended for use in patients seeking a topical treatment option for these common skin lesions.

Dosage and Administration

The affected area should be washed thoroughly. Soaking the wart in warm water for 5 minutes is optional but may enhance the effectiveness of the treatment. After washing, the area must be dried completely.

If necessary, the medicated plaster can be cut to fit the size of the wart. The plaster should then be applied directly to the wart.

This application should be repeated every 48 hours as needed, with a maximum treatment duration of up to 12 weeks.

Contraindications

Use of this product is contraindicated in the following situations:

Application on irritated, infected, or reddened skin is prohibited due to the potential for exacerbating these conditions. The product should not be applied to genital warts, facial warts, moles, birthmarks, or warts with hair, as these areas may be sensitive or require specialized treatment.

Additionally, the product must not come into contact with mucous membranes. Care should be taken to avoid contact with the eyes or face; in the event of accidental exposure to the eyes, thorough rinsing with water is necessary.

Warnings and Precautions

For external use only. This product is contraindicated for application on irritated, infected, or reddened skin, as well as on genital warts, facial warts, moles, birthmarks, or warts with hair growing from them. It should also not be applied to mucous membranes.

In the event of accidental ingestion, immediate medical assistance should be sought, or the Poison Control Center should be contacted without delay.

Healthcare professionals are advised to instruct patients to discontinue use and consult their physician if discomfort persists.

Side Effects

Patients should be aware that the product is intended for external use only. In the event that discomfort persists after application, it is advised to discontinue use and consult a healthcare professional.

Additionally, individuals with diabetes or poor blood circulation are encouraged to seek medical advice before using the product to ensure safety and appropriateness for their specific health conditions.

Drug Interactions

There are currently no documented drug interactions associated with this medication. Additionally, there is no information available regarding interactions with laboratory tests. As such, no specific recommendations for dosage adjustments or monitoring are warranted at this time.

Packaging & NDC

Below are the non-prescription pack sizes of Dermfree Wart Corn Remover (salicylic acid 40% wart corn remover). Columns show Packaging, Formulation Type, and Active Ingredient Strength.

Pediatric Use

Pediatric patients should be advised to keep this medication out of reach of children. In the event of accidental ingestion, immediate medical assistance should be sought, or contact with a Poison Control Center is recommended.

Geriatric Use

There is no specific information regarding the use of this medication in geriatric patients, including dosage adjustments, safety concerns, or special precautions. Healthcare providers should exercise caution when prescribing this medication to elderly patients, as individual responses may vary. Monitoring for potential adverse effects and therapeutic efficacy is recommended in this population.

Pregnancy

Pregnant patients should be aware that the safety of this medication during pregnancy has not been explicitly established. There are no available data regarding potential risks or fetal outcomes associated with the use of this medication in pregnant individuals. Healthcare professionals are advised to consider the potential benefits and risks when prescribing this medication to women of childbearing potential. It is recommended that patients inform their healthcare provider if they are pregnant, plan to become pregnant, or are breastfeeding. Further studies may be necessary to fully understand the implications of this medication on pregnancy and fetal development.

Lactation

There is no specific information available regarding the use of this medication in nursing mothers or its effects on lactation. Consequently, healthcare professionals should exercise caution when prescribing this medication to lactating mothers, as the potential risks to breastfed infants are not well characterized. It is advisable to consider the benefits of breastfeeding alongside the potential risks associated with the medication.

Renal Impairment

Patients with renal impairment may require dosage adjustments to ensure safety and efficacy. It is essential to monitor renal function tests in these individuals to assess their kidney status. Additionally, a reduced dose should be considered for patients with decreased creatinine clearance to mitigate the risk of adverse effects associated with impaired renal function.

Hepatic Impairment

Patients with hepatic impairment have not been specifically studied in clinical trials for this medication. Consequently, there is no available information regarding dosage adjustments, special monitoring requirements, or precautions for individuals with compromised liver function. It is recommended that healthcare providers exercise caution when prescribing this medication to patients with hepatic impairment, given the lack of data on its safety and efficacy in this population. Regular monitoring of liver function may be warranted in these patients to ensure safety and therapeutic effectiveness.

Overdosage

There is currently no specific information available regarding overdosage for this medication. Healthcare professionals are advised to monitor patients closely for any signs of adverse effects or symptoms that may arise from excessive dosing.

In the event of suspected overdosage, it is recommended that healthcare providers initiate supportive care and symptomatic treatment as necessary. Patients should be evaluated for potential complications, and appropriate interventions should be implemented based on clinical judgment.

For further guidance, healthcare professionals may refer to established protocols for managing drug overdosage or consult a poison control center.

Nonclinical Toxicology

No teratogenic or non-teratogenic effects have been reported in the available nonclinical studies. Additionally, there is no information regarding animal pharmacology and toxicology. The absence of data in these areas limits the understanding of the compound's potential effects in nonclinical settings.

Postmarketing Experience

No postmarketing experience details are provided in the insert.

Patient Counseling

Healthcare providers should advise patients to seek immediate medical assistance or contact a Poison Control Center if the product is swallowed. It is important to inform patients that the product should not be applied to irritated, infected, or reddened skin, as well as on genital warts, warts on the face, moles, birthmarks, or warts with hair growing from them, and on mucous membranes.

Patients should be made aware that if discomfort persists after application, they should discontinue use and consult a healthcare professional. Additionally, healthcare providers should emphasize the importance of avoiding contact with the eyes or face. In the event that the product comes into contact with the eyes, patients should rinse thoroughly with water.

Furthermore, patients with diabetes or poor blood circulation should be encouraged to consult their doctor before using the product to ensure safety and appropriateness of use.

Storage and Handling

The product is supplied in various package configurations, with specific NDC numbers available for identification. It is essential to store the product within a temperature range of 59°F to 86°F (15°C to 30°C) to maintain its efficacy and integrity. Proper storage conditions must be adhered to, ensuring that the product is kept in a suitable container that protects it from environmental factors. Special handling requirements should be observed to prevent any compromise to the product's quality.

Additional Clinical Information

No further data are available.